+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Comparative activity and toxicity of cis-diamminedichloroplatinum (DDP) and a combination of doxorubicin, cyclophosphamide, and DDP in disseminated transitional cell carcinomas of the urinary tract



Comparative activity and toxicity of cis-diamminedichloroplatinum (DDP) and a combination of doxorubicin, cyclophosphamide, and DDP in disseminated transitional cell carcinomas of the urinary tract



Journal of Clinical Oncology 3(4): 539-545



From October 1978 to October 1981, 135 patients with disseminated transitional cell carcinomas of the urinary tract, with either measurable or evaluable disease, were randomized to receive either cis-diamminedichloroplatinum (DDP) or cyclophosphamide (CTX), Adriamycin (ADR) (Adria Laboratories, Columbus, Ohio), and DDP (CAD). DDP was given at a dose of 60 mg/m2, CTX at 400 mg/m2, and ADR at 40 mg/m2 intravenously every three weeks. Patients over the age of 65 and those with prior radiation received 75% of the dose initially. The dose was escalated if only mild toxicity developed. Of the patients on the CAD arm, 34% developed grade 3 or 4 hematologic toxicity, as compared to 3% in patients on the DDP therapy. Of the 93 patients with measurable disease, 48 received DDP. Seventeen percent had a partial or complete remission, as compared to 33% of the 45 patients on the CAD arm (P = .09). The crude median survival of patients on DDP was 6.0 months as compared to 7.3 months in patients receiving CAD (P = .17). We conclude that the CAD combination is more toxic than DDP with, at best, very marginal benefit in survival.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 039614448

Download citation: RISBibTeXText

PMID: 3884746

DOI: 10.1200/jco.1985.3.4.539


Related references

Combination chemotherapy with cyclophosphamide, doxorubicin, and bleomycin for metastatic transitional cell carcinoma of the urinary tract. Cancer Treatment Reports 64(8-9): 1011-1013, 1980

Comparative activity and toxicity of cis di ammine di chloro platinum vs. cyclo phosphamide adriamycin and cis di ammine di chloro platinum in disseminated transitional cell carcinomas of the urinary tract. Proceedings of the American Association for Cancer Research & American Society of Clinical Oncology 22: 461, 1981

Chemotherapy in advanced transitional cell carcinoma of the urinary tract. Phase II trial of a combination of doxorubicin and cisplatin. Journal d'Urologie 96(7): 373-374, 1990

Doxorubicin hydrochloride, cyclophosphamide, and 5-fluorouracil combination in advanced prostate and transitional cell carcinoma. Urology 8(5): 459-464, 1976

Chemotherapy of disseminated seminoma with combination of cis-diamminedichloroplatinum (II) and cyclophosphamide. Cancer Clinical Trials 4(4): 423-427, 1981

Combination cyclophosphamide, doxorubicin, and cisplatin (CAP) chemotherapy for extensive non-small cell carcinomas of the lung. Cancer Treatment Reports 65(11-12): 955-958, 1981

Effect of diethyldithiocarbamate on toxicity of doxorubicin cyclophosphamide and cis diamminedichloroplatinum ii on mice hemopoietic progenitor cells. British Journal of Cancer 59(3): 371-374, 1989

Development of multiple transitional cell carcinomas in the urinary tract. Japanese Journal of Clinical Oncology 21(2): 110-114, 1991

Epidermal nevus with transitional cell carcinomas of the urinary tract. Journal of the American Academy of Dermatology 25(5 Pt 1): 856-858, 1991

Phase II evaluation of the combination of triazinate, cyclophosphamide, doxorubicin, and cis-diamminedichloroplatinum(II) in patients with advanced adenocarcinoma of the lung. Cancer Treatment Reports 64(8-9): 925-928, 1980

Cytogenetic investigation of transitional cell carcinomas of the upper urinary tract. Cancer Genetics & Cytogenetics 114(2): 117-120, 1999

Transitional cell carcinomas of the urinary tract in a colony of beagle dogs. Veterinary Pathology 26(6): 455-461, 1989

Laparoscopic approaches to transitional cell carcinomas of the upper urinary tract. Seminars in Surgical Oncology 12(2): 113-120, 1996

Cytogenetic analysis of upper urinary tract transitional cell carcinomas. Cancer Genetics & Cytogenetics 115(2): 123-127, 1999

Kit (CD117) immunoreactivity is rare in renal cell and upper urinary tract transitional cell carcinomas. Bju International 95(3): 315-318, 2005